Pharmacovigilance (PV) Market Segmentation, Scope and Driver Analysis to 2025

The global Pharmacovigilance (PV) Market is expected to reach USD 10.27 billion by 2025, according to a new report by Hexa Reports. The market is expected to witness growth at 13.1% CAGR owing to Increasing incidence of ADR is key driver for the growth of pharmacovigilance market. As of 2015, the U.S. FDA received approximately 253,017 serious adverse events and 44,693 deaths associated with adverse drug reactions (ADRs). This shows the potential demand for implementing safety and pharmacovigilance services over the forecast period.

Pharmacovigilance (PV) Market

According to World Health Organization’s (WHO) report on pharmaceuticals consumption, medicines to treat chronic diseases accounted for a larger proportion of the total volume of drug consumption in non-hospital set ups. Owing to this, there has been a significant rise in the number of medicines made available to healthcare consumers. Rising demand for drugs has significantly heightened the need for novel therapeutics development via extensive clinical trials, which is further expected to serve this market with lucrative opportunities.

Browse Detail Report With TOC @ https://www.hexareports.com/report/pharmacovigilance-pv-market

Major pharmaceutical companies are involved in extensive R&D initiatives for development of innovative therapeutic molecules. This has resulted in increased rate of drug development. Manufacturers are now focusing on remodeling their product development processes in an attempt to cater to patient needs across the globe. These factors are anticipated to fuel the demand for PV services during the forecast period.

Moreover, leading pharma companies in developed countries are focusing toward the outsourcing PV service in an attempt to reduce cost and minimize operational expenses. This is anticipated to serve as opportunity for contact research organizations in developing regions to gain more revenue share.

The companies are undertaking strategic initiatives such as collaboration with the PV service providers to get access to medical information and manage PV workflows. For instance, In April 2017, Accenture entered in a collaborative agreement with BioCelebrate to develop a platform for aggregating and analyzing clinical information for improvement in drug developing efficiency, thus enhancing its R&D capabilities.

Request A Sample copy of This Report @ https://www.hexareports.com/report/pharmacovigilance-pv-market/request-sample

Further Key Findings From the Study Suggest:

  • Phase IV held a dominant share owing to the extensive post marketing surveillance of pharmaceuticals and increasing number of ADR incidences in the market
  • Phase III is anticipated to grow with lucrative CAGR owing to increasing focus of pharmaceutical manufacturers on therapeutic development and safety monitoring
  • Contract outsourcing held a significant share of the PV market based on service provider owing to the increasing shift of pharmaceutical companies towards outsourcing of PV services with a view to reduce operational cost
  • Based on the type of service, spontaneous reporting held the largest share owing to its wide application in pharmacovigilance and associated benefits such as easy simulation of data sets for better drug comparison
  • Research organizations segment is anticipated to exhibit lucrative growth over forecast period owing to increasing R&D for the development of novel biologics and medical devices
  • The Asia Pacific market for pharmacovigilance is anticipated to show lucrative CAGR in the coming years
  • The industry participants are focusing towards increasing R&D activities for the development of better pharmacovigilance services.

For More Details Visit @ Hexa Reports

Clavulanic Acid Market Analysis by Application, Region and Services to 2022

This report studies Clavulanic Acid in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering

  • Eli Lilly and Company
  • Merck
  • Antibioticos
  • Sandoz
  • GSK
  • Daewoong
  • Sun Pharma
  • United Laboratories
  • NCPC Xiantai
  • Sinopharm Sandwich
  • CSPC Pharmaceutical

Browse Detail Report With TOC @ http://www.hexareports.com/report/global-clavulanic-acid-market-professional-survey-report-2017

By types, the market can be split into

  • Capsule
  • Tablet

By Application, the market can be split into

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Request A Sample copy of This Report @ http://www.hexareports.com/report/global-clavulanic-acid-market-professional-survey-report-2017/request-sample

By Regions, this report covers (we can add the regions/countries as you want)

  • North America
  • China
  • Europe
  • Southeast Asia
  • Japan
  • India

Table of Contents:

  • Global Clavulanic Acid Market Professional Survey Report 2017
  • Manufacturing Cost Structure Analysis of Clavulanic Acid
  • Technical Data and Manufacturing Plants Analysis of Clavulanic Acid
  • Global Clavulanic Acid Overall Market Overview
  • Clavulanic Acid Regional Market Analysis
  • Major Manufacturers Analysis of Clavulanic Acid
  • Development Trend of Analysis of Clavulanic Acid Market
  • Clavulanic Acid Marketing Type Analysis
  • Consumers Analysis of Clavulanic Acid

For More Details Visit @ Hexa Reports

Menthol Crystals Market Segmentation, Scope and Driver Analysis to 2021

Menthol Crystals Market Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).

The report firstly introduced the Menthol Crystals basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world’s main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The report includes six parts, dealing with:

  1. Basic information;
  2. The Asia Menthol Crystals Market;
  3. The North American Menthol Crystals Market;
  4. The European Menthol Crystals Market;
  5. Market entry and investment feasibility;
  6. The report conclusion.

Browse Detail Report With TOC @ http://www.hexareports.com/report/global-menthol-crystals-market-research-report-2017

Detail TOC of Menthol Crystals Market Report:

Part I Menthol Crystals Industry Overview

  • Chapter One Menthol Crystals Industry Overview
  • Chapter Two Menthol Crystals Up and Down Stream Industry Analysis

Part II Asia Menthol Crystals Industry (The Report Company Including the Below Listed But Not All)

  • Chapter Three Asia Menthol Crystals Market Analysis
  • Chapter Four 2012-2017 Asia Menthol Crystals Productions Supply Sales Demand Market Status and Forecast
  • Chapter Five Asia Menthol Crystals Key Manufacturers Analysis
  • Chapter Six Asia Menthol Crystals Industry Development Trend

Request A Sample copy of This Report @ http://www.hexareports.com/report/global-menthol-crystals-market-research-report-2017/request-sample

Part III North American Menthol Crystals Industry (The Report Company Including the Below Listed But Not All)

  • Chapter Seven North American Menthol Crystals Market Analysis
  • Chapter Eight 2012-2017 North American Menthol Crystals Productions Supply Sales Demand Market Status and Forecast
  • Chapter Nine North American Menthol Crystals Key Manufacturers Analysis
  • Chapter Ten North American Menthol Crystals Industry Development Trend

Part IV Europe Menthol Crystals Industry Analysis (The Report Company Including the Below Listed But Not All)

  • Chapter Eleven Europe Menthol Crystals Market Analysis
  • Chapter Twelve 2012-2017 Europe Menthol Crystals Productions Supply Sales Demand Market Status and Forecast
  • Chapter Thirteen Europe Menthol Crystals Key Manufacturers Analysis
  • Chapter Fourteen Europe Menthol Crystals Industry Development Trend

Part V Menthol Crystals Marketing Channels and Investment Feasibility

  • Chapter Fifteen Menthol Crystals Marketing Channels Development Proposals Analysis
  • Chapter Sixteen Development Environmental Analysis
  • Chapter Seventeen Menthol Crystals New Project Investment Feasibility Analysis

Part VI Global Menthol Crystals Industry Conclusions

  • Chapter Eighteen 2012-2017 Global Menthol Crystals Productions Supply Sales Demand Market Status and Forecast
  • Chapter Nineteen Global Menthol Crystals Industry Development Trend

For More Details Visit @ Hexa Reports

Canada Neurology Devices Market Segmentation, Scope and Driver Analysis to 2023

Canada Neurology Devices Market Outlook to 2023 provides key market data on the Canada Neurology Devices market. The report provides value, in millions of US dollars and volume (in units) within market categories – CSF Management, Interventional Neurology, Neurostimulation Devices, Neurosurgical Products, Radiosurgery and Neurological Diagnostic Equipment.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Browse Detail Report With TOC @ http://www.hexareports.com/report/canada-neurology-devices-market-outlook-to-2023

Scope

  • Market size and company share data for Neurology Devices market categories – CSF Management, Interventional Neurology, Neurostimulation Devices, Neurosurgical Products, Radiosurgery and Neurological Diagnostic Equipment.
  • Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided from 2009 to 2016 and forecast to 2023.
  • 2016 company shares and distribution shares data for each of the market categories.
  • Global corporate-level profiles of key companies operating within the Canada Neurology Devices market.
  • Key players covered include Medtronic plc, Boston Scientific Corp, St. Jude Medical LLC, LivaNova PLC and Others.

Request A Sample copy of This Report @ http://www.hexareports.com/report/canada-neurology-devices-market-outlook-to-2023/request-sample

Reasons To Buy

  1. Develop business strategies by identifying the key market categories poised for strong growth in the future.
  2. Develop market-entry and market expansion strategies.
  3. Design competition strategies by identifying who-stands-where in the market.
  4. Develop investment strategies by identifying the key market categories expected to register strong growth in the near future.
  5. What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

For More Details Visit @ Hexa Reports

Brazil Neurology Devices Market Segmentation, Scope and Driver Analysis to 2023

Brazil Neurology Devices Market Outlook to 2023 provides key market data on the Brazil Neurology Devices market. The report provides value, in millions of US dollars and volume (in units) within market categories – CSF Management, Interventional Neurology, Neurostimulation Devices, Neurosurgical Products, Radiosurgery and Neurological Diagnostic Equipment.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Browse Detail Report With TOC @ http://www.hexareports.com/report/brazil-neurology-devices-market-outlook-to-2023

Scope

  • Market size and company share data for Neurology Devices market categories – CSF Management, Interventional Neurology, Neurostimulation Devices, Neurosurgical Products, Radiosurgery and Neurological Diagnostic Equipment.
  • Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided from 2009 to 2016 and forecast to 2023.
  • 2016 company shares and distribution shares data for each of the market categories.
  • Global corporate-level profiles of key companies operating within the Brazil Neurology Devices market.
  • Key players covered include Medtronic plc, Boston Scientific Corp, St. Jude Medical LLC, LivaNova PLC and Others.

Request A Sample copy of This Report @ http://www.hexareports.com/report/brazil-neurology-devices-market-outlook-to-2023/request-sample

Reasons To Buy

  1. Develop business strategies by identifying the key market categories poised for strong growth in the future.
  2. Develop market-entry and market expansion strategies.
  3. Design competition strategies by identifying who-stands-where in the market.
  4. Develop investment strategies by identifying the key market categories expected to register strong growth in the near future.
  5. What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

For More Details Visit @ Hexa Reports

Mexico Neurology Devices Market Analysis by Application, Region and Services to 2023

Mexico Neurology Devices Market Outlook to 2023 provides key market data on the Mexico Neurology Devices market. The report provides value, in millions of US dollars and volume (in units) within market categories – CSF Management, Interventional Neurology, Neurostimulation Devices, Neurosurgical Products, Radiosurgery and Neurological Diagnostic Equipment.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Browse Detail Report With TOC @ http://www.hexareports.com/report/mexico-neurology-devices-market-outlook-to-2023

Scope

  • Market size and company share data for Neurology Devices market categories – CSF Management, Interventional Neurology, Neurostimulation Devices, Neurosurgical Products, Radiosurgery and Neurological Diagnostic Equipment.
  • Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided from 2009 to 2016 and forecast to 2023.
  • 2016 company shares and distribution shares data for each of the market categories.
  • Global corporate-level profiles of key companies operating within the Mexico Neurology Devices market.
  • Key players covered include Medtronic plc, Boston Scientific Corp, St. Jude Medical LLC, LivaNova PLC and Others.

Request A Sample copy of This Report @ http://www.hexareports.com/report/mexico-neurology-devices-market-outlook-to-2023/request-sample

Reasons To Buy

  1. Develop business strategies by identifying the key market categories poised for strong growth in the future.
  2. Develop market-entry and market expansion strategies.
  3. Design competition strategies by identifying who-stands-where in the market.
  4. Develop investment strategies by identifying the key market categories expected to register strong growth in the near future.
  5. What are the key distribution channels and what’s the most preferred mode of product distribution -Identify, understand and capitalize.

For More Details Visit @ Hexa Reports

BCG Vaccine Market Service Estimate and Trend Analysis to 2022

This report presents a comprehensive overview of the BCG Vaccine Market in Europe. This shares the history data information from 2012 to 2016, and forecast from 2017 to 2022. This report provides a detailed analysis of the market, its dynamics, structure, characteristics, main players, growth and demand drivers, etc. As a Detailed Analysis report, it covers all details inside analysis and opinion in BCG Vaccine industry.

This report focus Global and Europe market, it covers details players regions product type and other details as following:

Key Players

  • Merck
  • Sanofi Pasteur
  • Japan BCG Lab
  • China National Biotec
  • Serum Institute of India
  • Intervax

Browse Detail Report With TOC @ http://www.hexareports.com/report/global-and-europe-bcg-vaccine-market-analysis-and-outlook-to-2022

Key Regions

  • Germany
  • United Kingdom
  • France
  • Europe
  • United States
  • China
  • Japan
  • India
  • Others

Request A Sample copy of This Report @ http://www.hexareports.com/report/global-and-europe-bcg-vaccine-market-analysis-and-outlook-to-2022/request-sample

Key Product Type

by Drug Types

  • Immune BCG
  • Therapy BCG
  • by End Users
  • Pediatrics
  • Adults

Table Of Content

  • BCG Vaccine Product Overview
  • BCG Vaccine Top 30 Brands Profile
  • BCG Vaccine by Regions 2012-2022
  • BCG Vaccine by Brands 2012-2022
  • BCG Vaccine by Consumer 2012-2022

For More Details Visit @ Hexa Reports

Integrin Beta 7 Market Size, Scope, Overview, Drivers and Key Vendor Analysis by 2017

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The latest report Integrin Beta 7 Pipeline Review, H2 2017, outlays comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interactions involve the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. It binds to HIV-1 gp120 that allows the virus to enter GALT (major trigger of AIDS disease).  The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 1 and 2 respectively. Report covers products from therapy areas Gastrointestinal, Infectious Disease, Immunology and Oncology which include indications Ulcerative Colitis, Crohn’s Disease (Regional Enteritis), Human Immunodeficiency Virus (HIV) Infections (AIDS).

Browse Detail Report With TOC @ http://www.hexareports.com/report/integrin-beta-7-gut-homing-receptor-beta-subunit-or-itgb7-pipeline-review-h2-2017

Furthermore, this report also reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
  • The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Request A Sample copy of This Report @ http://www.hexareports.com/report/integrin-beta-7-gut-homing-receptor-beta-subunit-or-itgb7-pipeline-review-h2-2017/request-sample

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

Reasons To Buy

  1. Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  2. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  3. Identify and understand the targeted therapy areas and indications for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
  4. Identify the use of drugs for target identification and drug repurposing
  5. Identify potential new clients or partners in the target demographic
  6. Develop strategic initiatives by understanding the focus areas of leading companies
  7. Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

For More Details Visit @ Hexa Reports

Leptin Receptor Market Development Trends, Economic Impacts and Market Forecasts to 2017

Leptin Receptor Pipeline Review, H2 2017′; Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) Leptin receptor or LEP-R is a protein encoded by the LEPR gene. It acts as a receptor for hormone LEP/leptin. Upon binding it mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade. LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity.

Browse Detail Report With TOC @ http://www.hexareports.com/report/leptin-receptor-hub219-or-ob-receptor-or-cd295-or-lepr-pipeline-review-h2-2017

The report ‘Leptin Receptor Pipeline Review, H2 2017’ outlays comprehensive information on the Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration and Preclinical stages are 1 and 7 respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System and Oncology which include indications Obesity, Alzheimer’s Disease, Lipodystrophy, Type 2 Diabetes, Acquired Generalized Lipodystrophy (Lawrence Syndrome), Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome), Breast Cancer, Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome) and Type 1 Diabetes (Juvenile Diabetes).

Request A Sample copy of This Report @ http://www.hexareports.com/report/leptin-receptor-hub219-or-ob-receptor-or-cd295-or-lepr-pipeline-review-h2-2017/request-sample

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)
  • The report reviews Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics

Reasons To Buy

  1. Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  2. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  3. Identify and understand the targeted therapy areas and indications for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)
  4. Identify the use of drugs for target identification and drug repurposing
  5. Identify potential new clients or partners in the target demographic
  6. Develop strategic initiatives by understanding the focus areas of leading companies
  7. Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  8. Devise corrective measures for pipeline projects by understanding Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) development landscape
  9. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

For More Details Visit @ Hexa Reports